Emerging evidence has proven the robust role of tumor mutation burden (TMB) and immune cell infltration (ICI) in cancer immunotherapy. However, the precise efect of TMB and ICI on clear cell renal cell carcinoma (ccRCC) remains elusive and merits further investigation.